Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Duke University
Study ID
NCT07275359
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Metformin — DRUG
    All enrolled participants will receive open-label Metformin for a treatment period of 6 months.

Study Details

The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.

Key Dates

Start date
Sep 1, 2026
Status verified
Apr 2026
Primary completion
Sep 1, 2028
Completion
Oct 2, 2029

Study Design

Enrollment
45 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Metformin
    Metformin in COPD patients without diabetes

Primary Outcome Measure

Determine feasibility of metformin administration in older persons with COPD without diabetes [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Duke Asthma, Allergy, and Airway CenterDurhamNorth Carolina27705
Jessica Shier
[email protected]
919-684-9139
Christopher Mosher, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Durham, NC

By research site
Duke Asthma, Allergy, and Airway Center· Durham, NC

Related Studies